The HypoDE study, a randomized multi-center trial, showed that rtCGM use reduces the number of low glucose events (<55 mg/dl for at least 20 minutes) per 28 days from 10.4 to 3.4 events compared to SMBG (13.5 to 13.2 events) in MDI-treated type 1 diabetic patients with hypoglycemia problems. In this post-hoc analysis, we analyzed which baseline variables predict successful reduction of low glucose events. The criterion was a reduction to 0 events or by 50% from baseline. In a block-wise, multivariate logistic regression, demographic and medical variables, patient-reported-outcomes, biochemical hypoglycemia at baseline (based on 4-week masked rtCGM use), hours per day in time in range and hyperglycemia, and use of rtCGM were used as predictors. Model fit of the block-wise regression suggests that none of the baseline characteristics did predict hypoglycemia avoidance. However, entering use of rtCGM led to a rise of Nagelkerke´s R² from 0.061 to 0.331. This indicates that rtCGM use was the most important predictor for hypoglycemia avoidance. In the CGM Group, 76.1% of the patients compared to 26.3% in the Control group could avoid hypoglycemic events (Odds ratio 9.8, 95% CI 4.2 to 23.0). This suggests that rtCGM use is effective in patients with type 1 diabetes and hypoglycemia problems regardless of diabetes duration, glycemic control, severity of hypoglycemia problems, and exposure to biochemical hypoglycemia at baseline.
Characteristics | Nagelkerke´s R² | Delta - Nagelkerke´s R² | |
Block 1 | Demographic variables (age, diabetes Duration) | 0.005 | |
Block 2 | Block 1 + medical variables (HbA1c, severe hypoglycemia in the past 12 month, hypoglycemia unawareness | 0.022 | 0.017 |
Block 3 | Block 2 + Patient reported outcomes (fear of hypoglycemia, diabetes distress, satisfaction with glucose monitoring, self-reported health status) | 0.029 | 0.027 |
Block 4 | Block 3 + biochemical hypoglycemia at baseline (time spent ≤70 and ≤55 mg/dl per day, baseline low glucose Events) | 0.058 | 0.009 |
Block51 | Block 4 + time in range and time in hyperglycemia (>180 mg/dl) | 0.061 | 0.003 |
Block 6 | Block 5 + Treatment (rtCGM vs. SMBG) | 0.331 | 0.270 |
Characteristics | Nagelkerke´s R² | Delta - Nagelkerke´s R² | |
Block 1 | Demographic variables (age, diabetes Duration) | 0.005 | |
Block 2 | Block 1 + medical variables (HbA1c, severe hypoglycemia in the past 12 month, hypoglycemia unawareness | 0.022 | 0.017 |
Block 3 | Block 2 + Patient reported outcomes (fear of hypoglycemia, diabetes distress, satisfaction with glucose monitoring, self-reported health status) | 0.029 | 0.027 |
Block 4 | Block 3 + biochemical hypoglycemia at baseline (time spent ≤70 and ≤55 mg/dl per day, baseline low glucose Events) | 0.058 | 0.009 |
Block51 | Block 4 + time in range and time in hyperglycemia (>180 mg/dl) | 0.061 | 0.003 |
Block 6 | Block 5 + Treatment (rtCGM vs. SMBG) | 0.331 | 0.270 |
N. Hermanns: Speaker's Bureau; Self; Berlin-Chemie AG. Advisory Panel; Self; Abbott. Research Support; Self; Abbott. Speaker's Bureau; Self; Abbott. Research Support; Self; Berlin-Chemie AG. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Roche Diabetes Care Health and Digital Solutions. Research Support; Self; Ypsomed AG, Dexcom, Inc.. Speaker's Bureau; Self; Novo Nordisk Inc. L. Heinemann: Stock/Shareholder; Self; Profil Institute for Metabolic Research, ProSciento. Consultant; Self; Roche Diabetes Care Health and Digital Solutions. G. Freckmann: Speaker's Bureau; Self; Ascensia Diabetes Care. Research Support; Self; Ascensia Diabetes Care. Speaker's Bureau; Self; Roche Diabetes Care Health and Digital Solutions. Advisory Panel; Self; Roche Diabetes Care Health and Digital Solutions. Research Support; Self; Roche Diabetes Care Health and Digital Solutions. Advisory Panel; Self; Abbott, Novo Nordisk Inc.. Consultant; Self; Sensile Medical AG. Speaker's Bureau; Self; Ypsomed AG. D. Waldenmaier: None. D. Ehrmann: Speaker's Bureau; Self; Berlin-Chemie AG.